© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
September 08, 2021
Investigators find a precision medicine that can identify those with the rare disorder who may benefit from FDA-approved siltuximab.
September 02, 2021
The FDA has approved a second drug, zanubritinib, for the treatment of adult patients with Waldenström’s macroglobulinemia.
Lab values for sodium, potassium, chloride, magnesium, BUN, creatinine, glucose, and CO2.
August 31, 2021
Approved indications for idelalisib include relapsed chronic lymphocytic leukemia, small lymphocytic lymphoma, and follicular B-cell non-Hodgkin lymphoma.
August 27, 2021
The mutated genes in question, TET2 and DNMT3A, each influence the efficacy of treatment in different ways.
This designation could shorten the FDA review period to 8 months compared to the 12 months under Standard Review.
August 26, 2021
Alexandra S. Wolff, PharmD, BCOP, comments on her experience with CPX-351 in clinical practice and the potential to combine CPX-351 with targeted agents for AML.
Alexandra S. Wolff, PharmD, BCOP, explores the 5-year follow-up data from the phase 3 trial of CPX-351 in AML.
Expert continues discussion on important considerations for the optimal use if venetoclax in patients with AML, such as CYP3A4 and p-glycoprotein drug interactions.
Alexandra S. Wolff, PharmD, BCOP, highlights considerations for optimal use of venetoclax in patients with AML, such as tumor lysis syndrome prophylaxis.